4DN Stock Overview
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Denali Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$14.36 |
52 Week High | US$30.40 |
52 Week Low | US$14.36 |
Beta | 1.33 |
1 Month Change | -20.95% |
3 Month Change | -7.36% |
1 Year Change | -34.21% |
3 Year Change | -71.52% |
5 Year Change | -32.78% |
Change since IPO | -2.15% |
Recent News & Updates
Recent updates
Shareholder Returns
4DN | DE Biotechs | DE Market | |
---|---|---|---|
7D | -8.5% | -0.2% | 0.5% |
1Y | -34.2% | -22.8% | 1.3% |
Return vs Industry: 4DN underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 4DN underperformed the German Market which returned 2.3% over the past year.
Price Volatility
4DN volatility | |
---|---|
4DN Average Weekly Movement | 14.7% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4DN's share price has been volatile over the past 3 months.
Volatility Over Time: 4DN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 445 | Ryan Watts | www.denalitherapeutics.com |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
Denali Therapeutics Inc. Fundamentals Summary
4DN fundamental statistics | |
---|---|
Market cap | €2.07b |
Earnings (TTM) | -€135.38m |
Revenue (TTM) | €308.12m |
6.5x
P/S Ratio-14.7x
P/E RatioIs 4DN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4DN income statement (TTM) | |
---|---|
Revenue | US$330.53m |
Cost of Revenue | US$423.88m |
Gross Profit | -US$93.34m |
Other Expenses | US$51.88m |
Earnings | -US$145.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.02 |
Gross Margin | -28.24% |
Net Profit Margin | -43.94% |
Debt/Equity Ratio | 0% |
How did 4DN perform over the long term?
See historical performance and comparison